THE MARKET
MedTech: a structurally resilient sector with enduring industrial logic.
The global medical technology market is driven by demographic inevitability, regulatory barriers to entry, and sustained demand from healthcare systems. For disciplined investors, it offers attractive risk-adjusted returns, strong margins, and a consistent exit landscape shaped by strategic consolidation.
~$600 B
Global Market Size
medical technology worldwide
~5-6 %
Projected Annual Growth
2024–2030, device segments
27,000 +
MedTech companies in Europe
the majority are SMEs with revenue below €50 million
Top 5
Italy's Ranking in Europe
by number of manufacturers
Why healthcare is a defensive industrial sector
Healthcare occupies a structurally protected position in the economy. Demand is driven by chronic disease prevalence, ageing demographics, increased expectations for minimally invasive solutions, and the non-discretionary nature of care, not by economic cycles or consumer sentiment. These structural factors are compounded by growing regulatory complexity; authorities continuously raise the bar, creating compliance burdens that smaller, less-structured businesses struggle to absorb. This makes the sector demonstrably more resilient than most areas of private equity deployment.
Structural Drivers
- Ageing populations drive sustained demand for diagnostic and therapeutic devices
- Chronic disease prevalence creates recurring consumable and capital equipment cycles
- Growing patient expectations accelerate demand for minimally invasive, active-life solutions
- Regulatory frameworks act as durable barriers to entry, protecting established manufacturers
- Clinical adoption inertia ensures long switching cycles once a device enters hospital protocols
- Strategic consolidation by large medTech groups sustains a consistent and active exit landscape
“Engineering excellence in European healthcare SMEs is frequently not matched by capital structure, governance depth, or international infrastructure, creating a repeatable and addressable investment opportunity.”
The structural gap between technical quality and institutional maturity is the thesis. The market does not lack strong companies. It lacks structured capital combined with sector expertise to unlock its full potential.
Southern Europe: a concentration of underserved healthcare SMEs
Italy and the broader Southern European market represent an exceptional concentration of technically credible, founder-led healthcare businesses. These companies combine engineering precision and clinical credibility with structural constraints that limit scalable growth. Many are profitable, yet sub-scale.
1
Succession pressure
Generational transitions create windows for structured capital entry, often off-market and relationship-driven.
2
MDR regulatory burden
EU Medical Device Regulation compliance demands governance, documentation, and resources beyond most SMEs’ internal capacity.
3
Internationalisation constraints
Strong domestic revenues rarely translate into structured international expansion without commercial infrastructure and US market readiness.
Our investment focus within healthcare.
VITA Continental invests exclusively in high-end medical devices and diagnostics — technically complex segments where regulatory depth, clinical relationships, and sector expertise create genuine competitive advantage. We do not invest across healthcare broadly; sector exclusivity is structural and deliberate.
Surgical & Diagnostic
- High-end surgical devices
- Diagnostic imaging equipment
- In-vitro diagnostics
Interventional
- Minimally invasive instrumentation
- Orthopaedic & implantable devices
- Cardiovascular technology
Specialised
- Specialty diagnostics
- Technically complex niche devices
Services
- Clinics & Hospitals
- Laboratories
- Software
Target Company Profile
Founder-led or family-owned healthcare SMEs with up to €10 million in EBITDA. Technically strong, commercially constrained. Typically profitable, sub-scale, and facing at least one structural inflection point — succession, MDR pressure, internationalisation, or capital structure gaps.
Geographic scope
Primary deal flow originates in Italy, with selective European expansion into Switzerland, Germany, Austria, and Spain. Positioning is European from inception. No geography is structurally excluded; execution proximity is prioritised in the first phase.
Exit landscape: sustained strategic buyer activity.
The healthcare exit environment is consistently supported by large strategic acquirers — global device companies seeking technology, niche market access, or geographic consolidation — alongside healthcare-focused private equity funds. Exit value is driven by international expansion, US market positioning, regulatory robustness, and niche consolidation within typical holding periods of three to five years.
1
Primary exit routeStrategic Healthcare Acquirers
Global device companies and diagnostics groups acquiring niche specialists with proven clinical traction and established distributor networks
2
Secondary exit routeHealthcare-Focused PE Funds
Larger funds seeking pre-built platforms with governance maturity, international infrastructure, and de-risked regulatory exposure.
3
Value creation driversUS Readiness & MDR Compliance
US market positioning and full regulatory robustness are the two most impactful valuation levers at exit.